Hub : Traits :

Triglycerides

372 significantly associated models · 119 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 39328203 40737589 2 1 5.5e-08 7.0e-07 4.4e-01 98 PABPC4
2 1 61510619 64021096 4 1 3.7e-42 1.2e-42 1.0e+00 100 USP1
3 1 229499636 231115887 1 1 8.3e-14 8.1e-14 1.0e+00 100 GALNT2
4 2 20062043 21958745 3 3 1.0e-09 1.4e-45 7.0e-34 27 APOB C2orf43 HS1BP3
5 2 26592429 29344127 27 8 1.3e-87 5.7e-133 NaN NaN AC074117.10 CGREF1 FNDC4 NRBP1 PPM1G RP11-373D23.3
6 2 164657815 166170073 1 1 4.9e-08 1.6e-10 1.2e-05 53 GRB14
7 4 86819377 89140356 7 2 5.3e-10 3.9e-11 1.3e-02 86 PTPN13 RP11-529H2.2
8 5 155651738 157087764 1 1 1.5e-10 4.5e-11 7.7e-02 93 TIMD4
9 6 160071844 161571560 1 1 4.0e-07 1.7e-07 1.6e-02 79 SLC22A3
10 7 71652312 73843516 10 7 1.4e-66 1.2e-58 1.0e+00 100 MLXIPL POM121 TBL2 WBSCR22
11 8 10932868 12751157 4 1 4.6e-09 3.7e-07 8.7e-01 100 NEIL2
12 8 19064892 20858217 2 2 8.2e-94 1.5e-115 1.7e-17 86 LPL LZTS1
13 10 64195778 66034105 3 1 5.2e-12 7.6e-12 1.0e+00 100 NRBF2
14 11 60549966 62346131 7 1 8.6e-25 5.4e-24 2.1e-01 98 FADS3
15 11 115817454 117853613 10 8 9.7e-138 8.9e-122 NaN NaN PAFAH1B2 PCSK7 SIDT2 TAGLN ZNF259
16 12 57249600 58677299 1 1 2.8e-07 6.6e-10 4.8e-04 68 KIF5A
17 12 123716376 125270773 5 1 3.0e-09 1.6e-08 4.5e-01 98 RP11-380L11.3
18 15 42927984 44310790 1 1 1.8e-08 3.3e-11 1.0e-05 56 LCMT2
19 16 30347731 31860399 9 1 8.2e-09 1.2e-07 5.6e-01 99 BCKDK
20 16 56330832 57810318 1 1 6.8e-10 1.1e-12 2.3e-04 73 NLRC5
21 19 6374813 7771742 1 1 3.6e-07 2.1e-07 5.0e-02 86 ZNF557
22 19 18333894 20843876 8 1 2.0e-26 1.6e-29 1.1e-04 88 ATP13A1
23 20 32594714 34109427 2 1 8.3e-08 7.8e-08 2.3e-01 95 TP53INP2
24 20 43766067 45235570 5 2 2.3e-11 4.7e-18 8.3e-06 74 PLTP
25 22 37781874 39306784 3 1 1.7e-07 3.8e-08 5.4e-02 88 BAIAP2L2

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (including proxy) 1.66 1 1 3.0 0.00 1.0e+00 BCKDK
Crohns Disease (2017) 2.49 5 2 6.1 -0.74 1.5e-01 AC074117.10 FADS3 PPM1G RP11-373D23.3 TIMD4
Irritable Bowel Disease (IBD) 1.89 4 2 6.1 -0.91 9.1e-02 AC074117.10 FADS3 PPM1G RP11-373D23.3
Reaction Time 0.86 1 0 0.0 0.00 1.0e+00 RP11-380L11.3
Verbal and Numeric Reasoning (VNR) 1.55 1 0 0.0 0.00 1.0e+00 FADS3
Breast Cancer 1.56 1 1 3.0 0.00 1.0e+00 BAIAP2L2
Ovarian Cancer 1.46 1 0 0.0 0.00 1.0e+00 PAFAH1B2
Coronary Artery Disease (CAD) 2.73 3 0 0.0 0.00 1.0e+00 RP11-380L11.3 SLC22A3 ZNF259
Crohns Disease (2012) 2.26 4 1 3.0 0.09 9.1e-01 FADS3 RP11-373D23.3 TIMD4 USP1
Mean Putamen Volume 1.45 1 0 0.0 0.00 1.0e+00 TP53INP2
Fasting Glucose 5.05 5 4 12.1 -0.96 5.0e-04 AC074117.10 CGREF1 FADS3 PPM1G RP11-373D23.3
HDL Cholesterol 31.77 19 12 36.4 -0.60 2.9e-03 APOB C2orf43 FADS3 GALNT2 GRB14 HS1BP3 KIF5A LPL LZTS1 MLXIPL NLRC5 NRBF2 PABPC4 PCSK7 PLTP RP11-380L11.3 SIDT2 TAGLN ZNF259
LDL Cholesterol 15.83 12 10 30.3 0.60 3.1e-02 APOB ATP13A1 FADS3 HS1BP3 NLRC5 PAFAH1B2 PCSK7 SIDT2 SLC22A3 TIMD4 USP1 ZNF259
Neuroticism 1.32 1 1 3.0 0.00 1.0e+00 NEIL2
Schizophrenia 1.13 2 0 0.0 0.00 1.0e+00 AC074117.10 CGREF1
Blood Eosinophil Count 1.37 8 5 15.2 -0.05 9.0e-01 AC074117.10 BCKDK FADS3 LPL MLXIPL PAFAH1B2 SIDT2 ZNF259
Blood Platelet Count 7.23 25 21 63.6 0.13 4.9e-01 AC074117.10 ATP13A1 CGREF1 FADS3 FNDC4 GALNT2 KIF5A LCMT2 MLXIPL NRBF2 NRBP1 PABPC4 PAFAH1B2 PCSK7 POM121 PPM1G PTPN13 RP11-373D23.3 RP11-380L11.3 RP11-529H2.2 SIDT2 TAGLN TIMD4 USP1 ZNF259
Blood Red Count 2.11 20 10 30.3 -0.05 8.2e-01 AC074117.10 ATP13A1 BAIAP2L2 BCKDK FADS3 GALNT2 GRB14 HS1BP3 KIF5A LCMT2 NEIL2 NRBF2 NRBP1 PCSK7 PLTP PTPN13 RP11-373D23.3 RP11-380L11.3 RP11-529H2.2 TIMD4
Blood White Count 3.99 17 11 33.3 0.67 1.1e-03 AC074117.10 ATP13A1 BCKDK FADS3 FNDC4 MLXIPL NRBF2 NRBP1 PAFAH1B2 POM121 PPM1G RP11-373D23.3 RP11-380L11.3 RP11-529H2.2 SIDT2 TIMD4 USP1
Heel T-Score 1.35 8 5 15.2 0.03 9.3e-01 ATP13A1 BCKDK FADS3 PLTP PTPN13 RP11-380L11.3 RP11-529H2.2 USP1
BMI 1.77 11 5 15.2 -0.26 3.9e-01 AC074117.10 BCKDK GALNT2 GRB14 LCMT2 MLXIPL NRBF2 PABPC4 RP11-380L11.3 SLC22A3 TP53INP2
Height 1.54 23 13 39.4 -0.63 5.6e-04 AC074117.10 ATP13A1 BAIAP2L2 FADS3 FNDC4 GALNT2 LPL MLXIPL NRBF2 NRBP1 PABPC4 PAFAH1B2 PLTP POM121 PPM1G RP11-373D23.3 RP11-529H2.2 SLC22A3 TBL2 TP53INP2 WBSCR22 ZNF259 ZNF557
Waist Hip Ratio (WHR) 5.98 10 5 15.2 0.48 1.1e-01 ATP13A1 CGREF1 GRB14 LPL MLXIPL PABPC4 RP11-380L11.3 SLC22A3 TAGLN WBSCR22
Systolic Blood Pressure 1.89 10 6 18.2 0.89 1.8e-05 AC074117.10 FNDC4 GRB14 NRBF2 PAFAH1B2 PCSK7 PPM1G SIDT2 TAGLN ZNF557
Allergy or Eczema 1.62 4 1 3.0 0.10 9.0e-01 AC074117.10 NRBP1 PPM1G RP11-373D23.3
Cardiovascular Disease 5.22 18 12 36.4 0.90 4.6e-09 AC074117.10 APOB BCKDK FNDC4 LPL MLXIPL NRBF2 PABPC4 PAFAH1B2 PCSK7 PPM1G SIDT2 SLC22A3 TAGLN TIMD4 USP1 ZNF259 ZNF557
Hypothyroidism (self reported) 1.45 3 2 6.1 0.00 1.0e+00 FADS3 PTPN13 SIDT2
Respiratory disease 1.88 3 2 6.1 0.00 1.0e+00 FADS3 KIF5A PABPC4
Type 2 Diabetes (T2D) 3.65 7 3 9.1 -0.28 5.0e-01 AC074117.10 ATP13A1 GRB14 LPL PABPC4 PPM1G RP11-380L11.3
Lung FEV1/FVC ratio 1.30 3 2 6.1 0.00 1.0e+00 BCKDK NRBF2 PABPC4
Lung FVC 1.25 7 3 9.1 -0.73 6.4e-02 BCKDK NRBF2 PABPC4 PCSK7 SIDT2 TAGLN TP53INP2
Neuroticism 1.06 2 0 0.0 0.00 1.0e+00 BCKDK TP53INP2
Hair Pigment 2.85 14 7 21.2 0.14 6.1e-01 AC074117.10 FADS3 FNDC4 HS1BP3 KIF5A MLXIPL NRBP1 PABPC4 PCSK7 PPM1G SIDT2 TAGLN TBL2 TP53INP2
Tanning 5.15 5 3 9.1 -0.11 8.0e-01 AC074117.10 BAIAP2L2 MLXIPL PPM1G TP53INP2
Hand grip strength (left) 1.17 2 0 0.0 0.00 1.0e+00 BCKDK RP11-380L11.3
Number of treatments/medications taken 2.46 3 0 0.0 -0.69 3.1e-01 AC074117.10 FADS3 PPM1G
Frequency of depressed mood in last 2 weeks 1.13 1 0 0.0 0.00 1.0e+00 NEIL2
Relative age of first facial hair 1.48 2 0 0.0 0.00 1.0e+00 NRBF2 TP53INP2
Ever used hormone-replacement therapy (HRT) 2.05 1 0 0.0 0.00 1.0e+00 NRBP1
Systolic blood pressure, automated reading 1.31 2 1 3.0 0.00 1.0e+00 NEIL2 ZNF557
Angina 1.85 1 0 0.0 0.00 1.0e+00 SLC22A3
Supplements: Zinc 1.54 1 0 0.0 0.00 1.0e+00 NRBF2
Medication: Metformin 2.63 1 0 0.0 0.00 1.0e+00 AC074117.10
Diabetes (mother) 1.59 1 0 0.0 0.00 1.0e+00 ATP13A1
Impedance of leg (right) 1.97 10 7 21.2 -0.39 1.8e-01 AC074117.10 ATP13A1 BCKDK LCMT2 MLXIPL NEIL2 PABPC4 POM121 PTPN13 TP53INP2
Leg fat-free mass (left) 2.44 12 7 21.2 0.51 4.1e-02 AC074117.10 ATP13A1 BAIAP2L2 BCKDK LCMT2 MLXIPL PABPC4 PPM1G PTPN13 SLC22A3 TP53INP2 ZNF557
Trunk fat percentage 2.56 8 5 15.2 0.38 3.5e-01 BAIAP2L2 BCKDK CGREF1 GALNT2 GRB14 PABPC4 RP11-380L11.3 SLC22A3
Hand grip strength (right) 1.19 2 0 0.0 0.00 1.0e+00 RP11-380L11.3 TP53INP2
Relative age voice broke 1.23 1 0 0.0 0.00 1.0e+00 TP53INP2
Age when periods started (menarche) 1.30 1 1 3.0 0.00 1.0e+00 NRBF2
Heel bone mineral density (BMD) T-score, automated (left) 1.72 4 1 3.0 -0.54 4.6e-01 FADS3 NEIL2 RP11-380L11.3 RP11-529H2.2
High blood pressure 2.20 6 2 6.1 -0.63 1.8e-01 BCKDK NEIL2 NRBF2 PCSK7 SIDT2 ZNF557
Hayfever, allergic rhinitis or eczema 1.93 4 1 3.0 0.58 3.0e-01 AC074117.10 NRBP1 PPM1G RP11-373D23.3
Medication: Levothyroxine sodium 1.08 1 1 3.0 0.00 1.0e+00 FADS3
Sitting height 2.18 10 5 15.2 0.60 2.4e-02 AC074117.10 ATP13A1 BAIAP2L2 FADS3 MLXIPL PABPC4 PPM1G SLC22A3 TP53INP2 ZNF557
Body mass index (BMI) 1.81 6 3 9.1 -0.12 8.1e-01 BCKDK GALNT2 GRB14 NEIL2 NRBF2 RP11-380L11.3
Impedance of leg (left) 1.83 10 6 18.2 -0.39 1.9e-01 AC074117.10 ATP13A1 BCKDK LCMT2 MLXIPL NEIL2 PABPC4 POM121 PTPN13 TP53INP2
Leg predicted mass (left) 2.43 11 7 21.2 0.50 5.8e-02 AC074117.10 ATP13A1 BAIAP2L2 BCKDK LCMT2 MLXIPL PABPC4 PTPN13 SLC22A3 TP53INP2 ZNF557
Trunk fat mass 2.23 8 6 18.2 0.20 6.3e-01 BAIAP2L2 BCKDK CGREF1 GRB14 PABPC4 RP11-380L11.3 SLC22A3 TP53INP2
Waist circumference 1.41 2 1 3.0 0.00 1.0e+00 BCKDK PABPC4
Number of incorrect matches in round 1.37 1 1 3.0 0.00 1.0e+00 BCKDK
Alcohol usually taken with meals 1.09 1 0 0.0 0.00 1.0e+00 NRBF2
Nervous feelings 1.35 2 1 3.0 0.00 1.0e+00 BCKDK TP53INP2
Had menopause 3.58 4 3 9.1 0.89 4.2e-02 AC074117.10 FNDC4 NRBP1 PPM1G
Forced vital capacity (FVC) 0.87 1 1 3.0 0.00 1.0e+00 BCKDK
Heel bone mineral density (BMD) T-score, automated (right) 1.60 4 2 6.1 -0.54 4.6e-01 FADS3 NEIL2 RP11-380L11.3 RP11-529H2.2
Qualifications: None of the above 1.61 1 1 3.0 0.00 1.0e+00 NRBF2
Heart attack 1.99 2 0 0.0 0.00 1.0e+00 KIF5A SLC22A3
Allergy 1.73 5 1 3.0 -0.42 4.9e-01 FADS3 KIF5A NRBF2 NRBP1 RP11-373D23.3
Diabetes (self-reported) 3.09 3 1 3.0 0.70 3.0e-01 AC074117.10 PPM1G RP11-380L11.3
Medication: Simvastatin 7.90 10 5 15.2 -0.84 2.2e-03 AC074117.10 APOB ATP13A1 LPL NLRC5 PAFAH1B2 SLC22A3 TIMD4 USP1 ZNF259
Fluid intelligence score 1.60 1 0 0.0 0.00 1.0e+00 CGREF1
Illnesses of siblings 1.97 1 0 0.0 0.00 1.0e+00 BCKDK
Neuroticism score 1.34 2 2 6.1 0.00 1.0e+00 NEIL2 TP53INP2
Weight 2.25 9 6 18.2 0.54 6.8e-02 AC074117.10 BAIAP2L2 BCKDK GRB14 MLXIPL PABPC4 RP11-380L11.3 SLC22A3 TP53INP2
Impedance of arm (right) 3.94 13 11 33.3 -0.38 1.5e-01 AC074117.10 BAIAP2L2 BCKDK CGREF1 GRB14 MLXIPL NEIL2 NRBF2 POM121 PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Arm fat percentage (right) 2.23 6 4 12.1 0.36 4.9e-01 BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3
Trunk fat-free mass 2.84 11 6 18.2 0.69 4.6e-03 AC074117.10 BCKDK LCMT2 MLXIPL PPM1G PTPN13 RP11-373D23.3 RP11-380L11.3 SLC22A3 TP53INP2 ZNF557
Hip circumference 2.97 9 7 21.2 0.55 8.1e-02 BAIAP2L2 BCKDK GRB14 MLXIPL RP11-380L11.3 SLC22A3 TP53INP2 WBSCR22 ZNF557
Alcohol intake versus 10 years previously 2.72 1 1 3.0 0.00 1.0e+00 AC074117.10
Worrier / anxious feelings 1.22 1 1 3.0 0.00 1.0e+00 NEIL2
Number of live births 1.14 1 1 3.0 0.00 1.0e+00 FADS3
Forced expiratory volume in 1-second (FEV1) 0.81 1 1 3.0 0.00 1.0e+00 BCKDK
Pulse rate 2.22 2 1 3.0 0.00 1.0e+00 AC074117.10 FADS3
Qualifications: A levels/AS levels or equivalent 1.47 1 0 0.0 0.00 1.0e+00 NRBF2
Mouth/teeth dental problems: Dentures 1.21 1 0 0.0 0.00 1.0e+00 TP53INP2
Asthma 1.43 2 2 6.1 0.00 1.0e+00 FADS3 KIF5A
Medication: Cholesterol lowering 9.79 12 7 21.2 -0.91 6.6e-06 AC074117.10 APOB ATP13A1 LPL PAFAH1B2 PCSK7 PPM1G SIDT2 SLC22A3 TIMD4 USP1 ZNF259
Forced expiratory volume in 1-second (FEV1), Best measure 1.03 1 1 3.0 0.00 1.0e+00 BCKDK
Impedance of arm (left) 3.81 13 11 33.3 -0.38 1.4e-01 AC074117.10 BAIAP2L2 BCKDK CGREF1 GRB14 MLXIPL NEIL2 NRBF2 POM121 PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Arm fat mass (right) 2.05 8 4 12.1 0.07 8.7e-01 BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3 SLC22A3 TP53INP2
Trunk predicted mass 2.88 11 6 18.2 0.69 4.5e-03 AC074117.10 BCKDK LCMT2 MLXIPL PPM1G PTPN13 RP11-373D23.3 RP11-380L11.3 SLC22A3 TP53INP2 ZNF557
Standing height 1.70 15 10 30.3 0.52 3.1e-02 AC074117.10 ATP13A1 BAIAP2L2 FADS3 MLXIPL NRBF2 NRBP1 PABPC4 POM121 PPM1G RP11-373D23.3 RP11-529H2.2 SLC22A3 TP53INP2 ZNF557
Tense / 'highly strung' 1.30 2 0 0.0 0.00 1.0e+00 BCKDK TP53INP2
Hair/balding pattern: Pattern 4 0.73 1 1 3.0 0.00 1.0e+00 FADS3
Birth weight of first child 2.49 2 0 0.0 0.00 1.0e+00 ATP13A1 SIDT2
Blood clot in the leg (DVT) 1.61 1 0 0.0 0.00 1.0e+00 FADS3
Medication: Paracetamol 1.65 1 0 0.0 0.00 1.0e+00 FNDC4
Medication for cholesterol, blood pressure or diabetes 4.72 4 3 9.1 0.90 9.8e-02 APOB PAFAH1B2 PCSK7 ZNF259
Gout (self-reported) 8.10 6 4 12.1 -0.96 7.4e-06 AC074117.10 KIF5A MLXIPL POM121 PPM1G RP11-373D23.3
Hypothyroidism/myxoedema (self-reported) 1.15 2 0 0.0 0.00 1.0e+00 FADS3 PTPN13
Birth weight 1.22 2 1 3.0 0.00 1.0e+00 MLXIPL WBSCR22
High blood pressure (siblings) 1.99 2 0 0.0 0.00 1.0e+00 BCKDK NRBF2
Forced vital capacity (FVC), Best measure 1.12 2 1 3.0 0.00 1.0e+00 BCKDK PLTP
Body fat percentage 2.28 6 4 12.1 0.40 4.3e-01 BAIAP2L2 BCKDK CGREF1 GALNT2 GRB14 RP11-380L11.3
Leg fat percentage (right) 1.77 7 3 9.1 0.16 7.3e-01 BAIAP2L2 BCKDK GALNT2 GRB14 NRBF2 RP11-380L11.3 SIDT2
Arm fat-free mass (right) 3.08 10 7 21.2 0.68 7.7e-03 AC074117.10 BCKDK LCMT2 MLXIPL PPM1G PTPN13 RP11-373D23.3 RP11-380L11.3 SLC22A3 TP53INP2
Comparative body size at age 10 1.45 3 1 3.0 0.00 1.0e+00 AC074117.10 BCKDK TP53INP2
Worry too long after embarrassment 1.16 1 0 0.0 0.00 1.0e+00 TP53INP2
Seen a psychiatrist for nerves, anxiety, tension or depression 1.26 1 0 0.0 0.00 1.0e+00 FADS3
Wheeze or whistling in the chest in last year 1.56 2 0 0.0 0.00 1.0e+00 BCKDK FADS3
Age at first live birth 1.39 1 0 0.0 0.00 1.0e+00 NRBF2
Angina (self-reported) 1.90 1 0 0.0 0.00 1.0e+00 SLC22A3
Medication: Allopurinol 6.20 5 4 12.1 -0.96 4.2e-05 AC074117.10 KIF5A MLXIPL PPM1G RP11-373D23.3
Heart disease (mother) 1.65 1 0 0.0 0.00 1.0e+00 SLC22A3
Whole body fat mass 2.05 8 5 15.2 0.14 7.4e-01 BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3 SLC22A3 TP53INP2
Leg fat mass (right) 1.97 5 4 12.1 0.44 4.6e-01 BAIAP2L2 BCKDK GRB14 RP11-380L11.3 SLC22A3
Arm predicted mass (right) 3.10 10 7 21.2 0.71 4.8e-03 AC074117.10 BCKDK LCMT2 MLXIPL NEIL2 PPM1G PTPN13 RP11-373D23.3 SLC22A3 TP53INP2
Pulse rate, automated reading 3.35 7 3 9.1 -0.89 6.5e-04 AC074117.10 CGREF1 FADS3 MLXIPL PABPC4 PLTP PPM1G
Alcohol intake frequency. 3.98 6 4 12.1 -0.95 3.4e-05 AC074117.10 BCKDK CGREF1 MLXIPL PPM1G RP11-373D23.3
Comparative height size at age 10 1.72 7 4 12.1 0.39 3.4e-01 AC074117.10 ATP13A1 BAIAP2L2 PAFAH1B2 SLC22A3 TP53INP2 ZNF557
Overall health rating 1.79 2 1 3.0 0.00 1.0e+00 BCKDK CGREF1
Medication: Aspirin 1.82 1 0 0.0 0.00 1.0e+00 SLC22A3
Knee pain experienced in last month 1.41 2 0 0.0 0.00 1.0e+00 BCKDK PABPC4
Hypertension (Self-reported) 2.15 5 2 6.1 -0.57 3.2e-01 BCKDK NEIL2 NRBF2 SIDT2 ZNF557
Illnesses of father: Heart disease 2.57 3 1 3.0 0.00 1.0e+00 LPL RP11-380L11.3 SLC22A3
Forced expiratory volume in 1-second (FEV1), predicted 1.44 3 1 3.0 0.00 1.0e+00 FADS3 TP53INP2 ZNF557
Whole body fat-free mass 2.70 12 6 18.2 0.61 1.2e-02 AC074117.10 ATP13A1 BCKDK LCMT2 MLXIPL PABPC4 PPM1G PTPN13 RP11-373D23.3 SLC22A3 TP53INP2 ZNF557
Leg fat-free mass (right) 2.51 12 7 21.2 0.51 4.2e-02 AC074117.10 ATP13A1 BAIAP2L2 BCKDK LCMT2 MLXIPL PABPC4 PTPN13 RP11-373D23.3 SLC22A3 TP53INP2 ZNF557
Arm fat percentage (left) 2.24 6 4 12.1 0.37 4.7e-01 BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3
Average weekly red wine intake 0.87 1 0 0.0 0.00 1.0e+00 NRBF2
Diabetes diagnosed by doctor 3.11 4 1 3.0 0.76 1.3e-01 AC074117.10 ATP13A1 PPM1G RP11-380L11.3
Commuting to job workplace: Walk 1.27 1 0 0.0 0.00 1.0e+00 RP11-380L11.3
Medication for cholesterol 3.60 3 0 0.0 0.00 1.0e+00 AC074117.10 PAFAH1B2 USP1
Medication: Laxatives (e.g. Dulcolax, Senokot) 1.31 1 0 0.0 0.00 1.0e+00 CGREF1
Back pain experienced in last month 1.56 1 0 0.0 0.00 1.0e+00 APOB
Mineral and other dietary supplements 1.63 1 0 0.0 0.00 1.0e+00 NRBF2
Asthma (self-reported) 1.58 2 2 6.1 0.00 1.0e+00 FADS3 KIF5A
Medication: Aspirin 1.58 1 0 0.0 0.00 1.0e+00 SLC22A3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.41 1 1 3.0 0.00 1.0e+00 BCKDK
Whole body water mass 2.72 12 6 18.2 0.61 1.1e-02 AC074117.10 ATP13A1 BCKDK LCMT2 MLXIPL PABPC4 PPM1G PTPN13 RP11-373D23.3 SLC22A3 TP53INP2 ZNF557
Leg predicted mass (right) 2.51 12 7 21.2 0.52 4.1e-02 AC074117.10 ATP13A1 BAIAP2L2 BCKDK LCMT2 MLXIPL PABPC4 PTPN13 RP11-373D23.3 SLC22A3 TP53INP2 ZNF557
Arm fat mass (left) 2.01 8 4 12.1 0.06 8.8e-01 BAIAP2L2 BCKDK GALNT2 GRB14 PABPC4 RP11-380L11.3 SLC22A3 TP53INP2
Number of self-reported non-cancer illnesses 2.44 1 0 0.0 0.00 1.0e+00 AC074117.10
Average weekly champagne plus white wine intake 1.45 1 0 0.0 0.00 1.0e+00 FADS3
Miserableness 1.32 1 0 0.0 0.00 1.0e+00 NEIL2
Medication: Blood pressure 2.11 1 0 0.0 0.00 1.0e+00 NEIL2
High cholesterol (Self-reported) 17.73 19 11 33.3 -0.83 9.4e-07 AC074117.10 APOB ATP13A1 BCKDK CGREF1 FADS3 FNDC4 HS1BP3 LPL MLXIPL PAFAH1B2 PCSK7 PPM1G SIDT2 SLC22A3 TAGLN TIMD4 USP1 ZNF259
Medication: Bendroflumethiazide 1.57 1 0 0.0 0.00 1.0e+00 NEIL2
Medication: Atorvastatin 8.23 10 4 12.1 -0.95 7.3e-06 AC074117.10 APOB ATP13A1 BCKDK PAFAH1B2 PCSK7 PPM1G SLC22A3 USP1 ZNF259
Basal metabolic rate 2.54 12 5 15.2 0.57 2.0e-02 AC074117.10 ATP13A1 BCKDK LCMT2 MLXIPL PABPC4 PPM1G PTPN13 RP11-373D23.3 SLC22A3 TP53INP2 ZNF557
Leg fat percentage (left) 1.72 7 3 9.1 0.13 7.9e-01 BAIAP2L2 BCKDK GALNT2 GRB14 NRBF2 RP11-380L11.3 SIDT2
Arm fat-free mass (left) 2.76 10 6 18.2 0.70 5.4e-03 AC074117.10 BCKDK LCMT2 MLXIPL NEIL2 PPM1G PTPN13 RP11-373D23.3 SLC22A3 TP53INP2
Average weekly beer plus cider intake 1.08 1 1 3.0 0.00 1.0e+00 NRBF2
Irritability 2.67 5 2 6.1 0.27 6.6e-01 ATP13A1 BCKDK FADS3 NEIL2 TP53INP2
Risk taking 1.11 1 0 0.0 0.00 1.0e+00 CGREF1
Diastolic blood pressure, automated reading 1.78 4 3 9.1 -0.64 3.6e-01 BCKDK MLXIPL NEIL2 NRBF2
Vascular/heart problems diagnosed by doctor 2.25 4 2 6.1 0.54 4.6e-01 BCKDK NEIL2 NRBF2 ZNF557
Cholesterol lowering medication 10.13 13 6 18.2 -0.89 4.8e-06 AC074117.10 APOB BCKDK LPL PAFAH1B2 PCSK7 RP11-380L11.3 SIDT2 SLC22A3 TAGLN TIMD4 USP1 ZNF259
Pain experienced in last month 1.63 2 0 0.0 0.00 1.0e+00 BCKDK PABPC4
Basal cell carcinoma (self-reported) 1.12 1 0 0.0 0.00 1.0e+00 TP53INP2
Heart attack/myocardial infarction (self-reported) 2.02 2 0 0.0 0.00 1.0e+00 KIF5A SLC22A3
Heart disease (siblings) 1.88 1 1 3.0 0.00 1.0e+00 SLC22A3
Impedance of whole body 2.84 14 9 27.3 -0.46 6.4e-02 AC074117.10 BAIAP2L2 BCKDK CGREF1 GRB14 LCMT2 MLXIPL NEIL2 NRBF2 POM121 PTPN13 RP11-373D23.3 RP11-380L11.3 TP53INP2
Leg fat mass (left) 1.99 5 4 12.1 0.42 4.8e-01 BAIAP2L2 BCKDK GRB14 RP11-380L11.3 SLC22A3
Arm predicted mass (left) 2.85 10 6 18.2 0.69 6.0e-03 AC074117.10 BCKDK LCMT2 MLXIPL NEIL2 PPM1G PTPN13 RP11-373D23.3 SLC22A3 TP53INP2

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 7 0.2065 1.71
GTEx Adipose Visceral Omentum 10 0.5051 2.13
GTEx Adrenal Gland 5 0.3509 1.51
GTEx Artery Aorta 10 0.3460 1.67
GTEx Artery Coronary 4 0.3457 1.72
GTEx Artery Tibial 18 0.4942 1.69
GTEx Brain Caudate basal ganglia 1 0.1115 1.42
GTEx Brain Cerebellar Hemisphere 5 0.3444 1.49
GTEx Brain Cerebellum 6 0.3109 1.70
GTEx Brain Cortex 3 0.2979 1.62
GTEx Brain Frontal Cortex BA9 3 0.3337 1.40
GTEx Brain Hippocampus 1 0.1957 1.53
GTEx Brain Hypothalamus 0 0.0000 1.42
GTEx Brain Nucleus accumbens basal ganglia 2 0.2364 1.55
GTEx Brain Putamen basal ganglia 1 0.1647 1.47
GTEx Breast Mammary Tissue 4 0.2089 1.54
GTEx Breast Mammary Tissue (Male) 1 0.0861 1.53
GTEx Breast Mammary Tissue (Female) 8 0.5070 1.64
GTEx Cells EBV-transformed lymphocytes 3 0.2166 1.69
GTEx Cells Transformed fibroblasts 16 0.3914 1.91
GTEx Colon Sigmoid 5 0.3501 1.75
GTEx Colon Transverse 3 0.1501 1.60
GTEx Esophagus Gastroesophageal Junction 5 0.3569 1.86
GTEx Esophagus Mucosa 12 0.3713 1.69
GTEx Esophagus Muscularis 10 0.3184 1.65
GTEx Heart Atrial Appendage 4 0.2594 1.63
GTEx Heart Left Ventricle 4 0.2699 1.60
GTEx Liver 3 0.4310 1.62
GTEx Lung 10 0.3582 1.67
GTEx Muscle Skeletal 7 0.2489 1.62
GTEx Nerve Tibial 12 0.2852 1.66
GTEx Ovary 3 0.3386 1.87
GTEx Pancreas 3 0.1881 1.65
GTEx Pituitary 1 0.0911 1.64
GTEx Prostate 4 0.4914 1.75
GTEx Skin Not Sun Exposed Suprapubic 7 0.2917 1.81
GTEx Skin Sun Exposed Lower leg 10 0.2832 1.78
GTEx Small Intestine Terminal Ileum 0 0.0000 1.49
GTEx Spleen 5 0.3618 1.71
GTEx Stomach 3 0.2113 1.69
GTEx Testis 8 0.2600 1.86
GTEx Thyroid 18 0.4645 1.85
GTEx Uterus 1 0.1802 1.53
GTEx Vagina 1 0.1623 1.95
GTEx Whole Blood 13 0.6739 1.87
METSIM Adipose 20 0.4420 1.76
NTR Blood 11 0.4616 1.74
ROSMAP Brain Pre-frontal Cortex 18 0.4202 1.82
YFS Blood 18 0.3943 1.73
CommonMind Brain Pre-frontal Cortex 16 0.3031 1.75
TCGA Breast Tumor 0 0.0000 1.43
TCGA Breast Normal 13 0.3148 1.53
TCGA Ovarian Tumor 7 0.2426 1.48
TCGA Prostate Tumor 9 0.2655 1.57